GARDEN GROVE, Calif., May 16, 2011 /PRNewswire/ — HYCOR
Biomedical, Inc., a leading manufacturer and marketer of in vitro
diagnostic products for the global allergy, autoimmune and
urinalysis markets, together with owner Linden, LLC, today
announced the appointments of Vijay Aggarwal, Ph.D. and James
Koziarz, Ph.D., to its Board of Directors as part of its global
growth strategy.
“We are thrilled to welcome Drs. Aggarwal and Koziarz to the
HYCOR team and are confident they will have meaningful impact in
areas critical for the company’s continued growth,” said Richard
Novak, Chairman of HYCOR’s Board of Directors, and Operating
Partner at Linden, LLC. “Both of these gentlemen have extensive
backgrounds in clinical diagnostics for market leading companies,
and we are certain that HYCOR will benefit from their guidance in
the near and long term.”
Dr. Aggarwal brings more than 30 years of experience and
leadership in the pharmaceutical and diagnostics industries, having
served in senior management positions for a number of leading
companies, including Quest Diagnostics, IBT Laboratories and
SmithKline Beecham. As Director, Dr. Aggarwal will support the
HYCOR management team in a variety of capacities with a particular
focus on channel development in clinical laboratories.
Dr. Koziarz joins HYCOR’s Board after a distinguished 25 year
career at Abbott Laboratories, where he held several senior
management and executive positions, including Corporate Vice
President for Diagnostic Products Research & Development. Dr.
Koziarz is also an active advisor to several leading life sciences
companies. As Director, Dr. Koziarz will support the HYCOR
management team on next generation assay and platform development
strategies for global customers.
“We are pleased to have the opportunity to partner with these
two leaders in clinical diagnostics and are confident it will
benefit HYCOR, the healthcare professionals and pati
‘/>”/>
